Novel ventriculo­peritoneal shunt in Alzheimer´s disease cerebrospinal fluid biomarkers

Silverberg, Gerald D.; Mayo, Martha; Saul, Thomas; Carvalho, Joan; McGuire, Dawn

doi:10.1586/14737175.4.1.97

Cited by 18 publications

(13 citation statements)

References 80 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The COGNIshunt® is a ventriculo-peritoneal shunt, which differs only from shunts used to treat hydrocephalus in that it has been engineered to allow much lower drainage of the CSF (Silverberg et al 2004). By improving CSF circulation and turnover, the COGNIshunt® is hypothesized to increase clearance of Aβ peptides, aggregated tau, and other inflammatory mediators from the CNS (Silverberg et al 2004).…”

Section: Ventriculo-peritoneal Shuntmentioning

confidence: 99%

See 1 more Smart Citation

Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications

Creed

Milgram

2010

AGE

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most prevalent form of dementia, affecting an estimated 4.8 million people in North America. For the past decade, the amyloid cascade hypothesis has dominated the field of AD research. This theory posits that the deposition of amyloid-beta protein (Abeta) in the brain is the key pathologic event in AD, which induces a series of neuropathological changes that manifest as cognitive decline and eventual dementia. Based on this theory, interventions that reduce Abeta burden in the brain would be expected to alleviate both the neuropathological changes and dementia, which characterize AD. Several diverse pharmacological strategies have been developed to accomplish this. These include inhibiting the formation of Abeta, preventing the aggregation of Abeta into insoluble aggregates, preventing the entry of Abeta into the brain from the periphery and enhancing the clearance of Abeta from the central nervous system. To date, no amyloid-modifying therapy has yet been successful in phase 3 clinical trials; however, several trials are currently underway. This article provides a review of the status of amyloid-modifying therapies and the implications for the amyloid cascade hypothesis.

show abstract

Section: Ventriculo-peritoneal Shuntmentioning

confidence: 99%

“…By improving CSF circulation and turnover, the COGNIshunt® is hypothesized to increase clearance of Aβ peptides, aggregated tau, and other inflammatory mediators from the CNS (Silverberg et al 2004).…”

Section: Ventriculo-peritoneal Shuntmentioning

confidence: 99%

Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications

Creed

Milgram

2010

AGE

View full text Add to dashboard Cite

show abstract

“…Cerebrospinal fluid is not readily changed to a fluid of uniform properties as demonstrated by attempts to change the flow rate of cerebrospinal fluid by surgical means. These attempts were made in cases where a decrease in the flow rate of the cerebrospinal fluid was reported in individuals displaying Alzheimer's Disease [20]. The attempts were without any effect [21].…”

Section: Discussionmentioning

confidence: 99%

The Physical Chemistry of Brain and Neural Cell Membranes: An Overview

Robertson

2010

Neurochem Res

View full text Add to dashboard Cite

The formation of cell membranes through the physical-chemical interaction of two hydrophilic colloidal fluids is applied to the formation of the membranes of brain and neural cells. Also described is the membrane mechanism of transfer of ions and compounds necessary for brain and neural cell functions into the cerebrospinal fluid through the blood-brain barrier. Changes in the cerebrospinal fluid giving rise to degradation of brain and neural cells and the formation of precipitates within the brain are considered. Monitoring of electrolyte changes in metabolic fluids is shown to be a possible method of predicting the onset of degenerate brain conditions.

show abstract

“…Accumulating evidence indicates a high correlation between NPH and AD neuropathological findings. Indeed, patients with clinical and radiological evidence of NPH appear to have a higher than expected coincidence of AD pathologic changes involving plaques and tangles, as demonstrated in cortical biopsy samples obtained at shunt implantation [43][44][45][46][47]. In a series of 27 cases of NPH, Bech et al, [45] reported on 6 patients (22%) presenting with ADlike lesions.…”

Section: Changes In the Secretory Process Of The Choroid Plexusmentioning

confidence: 98%

The Valsalva Maneuver and Alzheimers Disease: Is there a link?

Wostyn

Audenaert²,

Deyn

2009

CAR

View full text Add to dashboard Cite

Recent research findings provide evidence for Alzheimer's disease-related changes in brain diseases, such as normal pressure hydrocephalus and traumatic brain injury, and in glaucoma at the level of the retinal ganglion cells. This is a group of diseases that affect central nervous system tissue and are characterized by elevation of intracranial or intraocular pressure and/or local shear stress and strain. This strengthens the possibility that Alzheimer-type changes in these diseases may result at least in part from exposure of central nervous system tissue to elevated mechanical load. As activities or diseases with significant Valsalva effort can generate increased intracranial pressures, we hypothesize that individuals who frequently perform strong Valsalva maneuvers (e.g., long hours of repetitive heavy lifting, sequences of blows during the playing of a wind instrument, forceful and repetitive cough, bearing-down efforts during parturition) may be more susceptible to developing Alzheimer's disease. In this paper, we discuss three hypotheses about the mechanisms by which extensive use of the Valsalva maneuver might contribute to the neuropathogenesis of Alzheimer's disease: via mechanical stress-induced events in the hippocampus and/or via changes in the secretory process of the choroid plexus and/or via hemodynamic changes in cerebral blood flow. If confirmed, this hypothesis could have implications in clinical practice.

show abstract

Novel ventriculoperitoneal shunt in Alzheimer´s disease cerebrospinal fluid biomarkers

Cited by 18 publications

References 80 publications

Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications

Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications

The Physical Chemistry of Brain and Neural Cell Membranes: An Overview

The Valsalva Maneuver and Alzheimers Disease: Is there a link?

Contact Info

Product

Resources

About

Novel ventriculo­peritoneal shunt in Alzheimer´s disease cerebrospinal fluid biomarkers

Cited by 18 publications

References 80 publications

Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications

Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications

The Physical Chemistry of Brain and Neural Cell Membranes: An Overview

The Valsalva Maneuver and Alzheimers Disease: Is there a link?

Contact Info

Product

Resources

About

Novel ventriculoperitoneal shunt in Alzheimer´s disease cerebrospinal fluid biomarkers